Living Cell Technologies closes IPO
Friday, 27 August, 2004
Living Cell Technologies has closed its IPO after raising AUD$6.36 million from institutional and retail clients of underwriting stockbroker Taylor Collinson.
The company is expected to move from the Newcastle stock exchange (NSX) to the ASX on September 1, and has been suspended from trading on the NSX in preparation.
"LCT is a unique biotechnology company with an international infrastructure, significant scientific and commercial potential and a clear path to market. Transferring to the ASX is a significant and strategic step in our development and the keen interest in our capital raising not only validates our hard work to date but will underscore continued success in further developing our unique technology," said CEO David Collinson in a statement.
Vanillin flavouring in vapes may disrupt embryo development
Vanillin — a common flavouring chemical in e-cigarettes — may disrupt the normal...
Heart valve tissues created from stem cells
The breakthrough should help advance our understanding into how human heart valves develop,...
Breast augmentation procedure uses 3D-printed scaffolds
3D-printed scaffold technology from medtech company BellaSeno has been used in a primary breast...
